93 completed, 57 recruiting, 35 terminated, 25 unknown. 253 Phase 2, 42 Phase 1, 23 Phase 3.
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 10 | 2028-02-01 | 2026-04-13 |
| A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated Focal Segmental Glomerulosclerosis, and Minimal Change Disease Sibeprenlimab - Primary Membranous Nephropathy, Minimal Change Disease | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 20 | 2026-12-15 | 2026-10-06 |
| A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab - Immunoglobulin A Nephropathy | Phase 2 | Not yet recruiting | Biogen | 25 | 2026-11-16 | 2026-10-22 |
| A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN ARGX-121, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 2 | Recruiting | argenx | 120 | 2026-11-05 | 2026-10-27 |
| Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy Forxiga - Glomerulonephritis | Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2026-11-01 | 2026-06-22 |
| An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases ManNAc - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | National Human Genome Research Institute (NHGRI) | 30 | 2026-10-27 | 2026-10-30 |
| CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus Autologous CD19-Directed CAR-T Cells Manufactured at Ribeirão Preto Blood Center - Lupus Erythematosus, Systemic | Phase 1 / Phase 2 | Not yet recruiting | University of Sao Paulo | 16 | 2026-10-01 | 2026-10-29 |
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy C-CAR168 - Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE) | Phase 2 | Not yet recruiting | AbelZeta Inc. | 50 | 2026-09-30 | 2026-10-13 |
| Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis TranspoCART19 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Recruiting | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 10 | 2026-09-23 | 2026-10-01 |
| Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial Obinutuzumab - Lupus Nephritis, Membranous Nephropathy | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 65 | 2026-09-02 | 2026-07-23 |
| A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | Phase 2 | Recruiting | iCell Gene Therapeutics | 20 | 2026-09-01 | 2026-09-17 |
| Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy Mycophenolate Mofetil (MMF), Prednisolon - IgA Nephropathy | Phase 2 | Not yet recruiting | Shaheed Suhrawardy Medical College and Hospital | 104 | 2026-09-01 | 2026-08-25 |
| Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) QLS7305 Injection - IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-08-10 | 2026-07-28 |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis FT819 - Lupus Nephritis, Systemic Lupus Erythematosus | Phase 2 | Recruiting | Fate Therapeutics | 53 | 2026-07-27 | 2026-09-14 |
| A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy HRS-5965 Capsules - Primary IgA Nephropathy | Phase 2 | Recruiting | Chengdu Suncadia Medicine Co., Ltd. | 380 | 2026-07-06 | 2026-07-22 |
| C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease C-CAR168 - Lupus Nephritis (LN) | Phase 1 / Phase 2 | Withdrawn | AbelZeta Inc. | 2026-07-01 | 2026-07-16 | |
| SLN12140 in Adult Participants With IgA Nephropathy in China SLN12140, Placebo - IgA Nephropathy (IgAN) | Phase 2 | Not yet recruiting | Linno Pharmaceuticals, Inc. | 48 | 2026-05-29 | 2026-04-28 |
| Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis Dapagliflozin (10Mg Tab) along with standard medical therapy, Proteinuria Quantification - Lupus Nephritis (LN), Chronic Kidney Disease | Phase 1 / Phase 2 | Active not recruiting | Hospital Civil Juan I. Menchaca | 30 | 2026-05-28 | 2026-07-01 |
| A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis Mosunetuzumab - Lupus, Systemic Lupus Erythematosus | Phase 2 | Recruiting | Hoffmann-La Roche | 30 | 2026-05-25 | 2026-10-19 |
Showing 20 of 253. Sign in to see all of them.
Lupus Nephritis (100) · Glomerulonephritis, IGA (83) · Lupus Erythematosus, Systemic (40) · Glomerulosclerosis, Focal Segmental (34) · Glomerulonephritis, Membranous (30) · Proteinuria (29) · Kidney Diseases (25) · Autoimmune Diseases (18) · Nephrotic Syndrome (17) · Nephritis (14) · Nephrosis, Lipoid (14) · Glomerulonephritis, Membranoproliferative (12) · Renal Insufficiency, Chronic (9) · Diabetic Nephropathies (7)
Female Urogenital Diseases (253) · Female Urogenital Diseases and Pregnancy Complications (253) · Male Urogenital Diseases (253) · Urogenital Diseases (251) · Urologic Diseases (246) · Nephritis (239) · Kidney Diseases (228) · Immune System Diseases (212) · Autoimmune Diseases (189) · Skin and Connective Tissue Diseases (107) · Connective Tissue Diseases (104) · Lupus Erythematosus, Systemic (61) · Pathological Conditions, Signs and Symptoms (46) · Signs and Symptoms (32)
Cyclophosphamide (19) · Mycophenolic Acid (18) · Prednisone (12) · Rituximab (12) · Methylprednisolone (7) · fludarabine (7) · Cyclosporine (5) · Prednisolone (5) · TACI receptor-IgG Fc fragment fusion protein (5) · belimumab (5) · felzartamab (5) · telitacicept (5) · Adrenal Cortex Hormones (4) · Azathioprine (4) · Sirolimus (4)
Novartis Pharmaceuticals (13) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (10) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Alexion Pharmaceuticals, Inc. (5) · Amgen (5) · Biogen (4) · Mayo Clinic (4) · Otsuka Pharmaceutical Development & Commercialization, Inc. (4) · Aurinia Pharmaceuticals Inc. (3) · Beijing GoBroad Hospital (3) · Centre Hospitalier Universitaire de Nice (3) · GlaxoSmithKline (3) · HI-Bio, A Biogen Company (3) · Haisco Pharmaceutical Group Co., Ltd. (3) · Hoffmann-La Roche (3)
United States (119) · China (70) · United Kingdom (47) · Spain (41) · Australia (36) · France (33) · Germany (33) · Italy (33) · South Korea (31) · Taiwan (24) · Canada (23) · Poland (22) · Netherlands (21) · Argentina (20) · Brazil (20)
David Wofsy, MD (3) · Fernando C. Fervenza, M.D., Ph.D. (3) · Betty Diamond, M.D. (2) · Betty Diamond, MD (2) · Connie L Davis, MD (2) · David Wofsy, M.D. (2) · Fernando Fervenza, MD (2)
PMID 38299639, PMID 34778952, PMID 35224732, PMID 37528520, PMID 38724717, PMID 40465397, PMID 26032537, PMID 39899371, PMID 40337980, PMID 36423588, PMID 38334499, PMID 39513526, PMID 39673415, PMID 40938675, PMID 15807196, PMID 17660026, PMID 17699247, PMID 19073787, PMID 19932542, PMID 20605876, PMID 21310077, PMID 21325353, PMID 21356124, PMID 22325903, PMID 23977072, PMID 25403681, PMID 25457107, PMID 25779381, PMID 26087670, PMID 26198842, PMID 26562836, PMID 27110697, PMID 28363480, PMID 28478399, PMID 29996800, PMID 30177021, PMID 30361325, PMID 30428931, PMID 31269364, PMID 31907076, PMID 32231244, PMID 32755035, PMID 32903623, PMID 33107592, PMID 33311560, PMID 33685975, PMID 33693991, PMID 33767059, PMID 34124781, PMID 34169203
2018 (5), 2023 (5), 2015 (4), 2017 (4), 2019 (4), 2025 (3), 2014 (2), 2016 (2), 2005 (1), R01AR079124 (1), R01DK049368 (1), R01MD016401 (1), R21DK077329 (1), R33DK070341 (1), UL1RR024150 (1)